0.82%
6.70%
18.21%
35.89%
83.54%
173.24%
392.08%
AI Spotlight on ARGX
Company Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France.Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases.
In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor.The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH.argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Market Data
| Last Price | 640.2 |
| Change Percentage | 0.82% |
| Open | 642.2 |
| Previous Close | 635 |
| Market Cap ( Millions) | 38899 |
| Volume | 4711 |
| Year High | 658 |
| Year Low | 322.5 |
| M A 50 | 606.63 |
| M A 200 | 482.19 |
Financial Ratios
| FCF Yield | -0.52% |
| Dividend Yield | 0.00% |
| ROE | -2.75% |
| Debt / Equity | 0.80% |
| Net Debt / EBIDTA | 2963.09% |
| Price To Book | 9.38 |
| Price Earnings Ratio | -392.21 |
| Price To FCF | -191.5 |
| Price To sales | 17.91 |
| EV / EBITDA | -823.82 |
News
- Jan -30 - Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
- Jan -30 - Exploring High Growth Tech Stocks With Promising Potential
- Jan -23 - Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?
- Jan -23 - Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?
- Jan -13 - argenx Highlights 2025 Strategic Priorities
- Jan -06 - argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
- Jan -01 - Exploring High Growth Tech Stocks for January 2025
- Dec -28 - Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment
- Dec -27 - argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
- Dec -23 - Is Argenx SE (ARGX) the Best Performing Biotech Stock in 2024?
- Dec -12 - Here’s Why Novo Nordisk A/S (NVO) Fell in Q3
- Dec -09 - Should You Increase Your Holdings in argenx SE (ARGX)?
- Dec -03 - Three Stocks Estimated To Be Undervalued In December 2024
- Dec -03 - Spotlight On High Growth Tech Stocks This December 2024
- Dec -02 - Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?
- Nov -26 - argenx to Present at Upcoming Investor Conferences
- Nov -22 - Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
- Nov -20 - argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
- Nov -18 - Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
- Nov -11 - Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Antibody-based Medicines
Expected Growth : 9.27 %
What the company do ?
Antibody-based medicines from argenx SE are innovative therapies that utilize antibodies to target specific disease-causing proteins, offering potential treatments for autoimmune diseases and cancer.
Why we expect these perspectives ?
Argenx SE's antibody-based medicines exhibit strong growth driven by increasing demand for targeted therapies, expanding treatment options for rare diseases, and strategic partnerships. The company's innovative pipeline, including efgartigimod, and its potential to address unmet medical needs in autoimmune diseases, further fuels growth. Additionally, argenx's strong financial position and operational efficiency enable investments in R&D, contributing to the 9.27% growth rate.
Argenx Se Products
| Product Range | What is it ? |
|---|---|
| Efgartigimod | A human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), reducing the concentration of disease-causing autoantibodies in autoimmune diseases. |
| ARGX-117 | A human monoclonal antibody that targets C2, a key component of the classical complement pathway, to treat severe autoimmune diseases. |
| ARGX-113 | A human monoclonal antibody that targets the neonatal Fc receptor (FcRn), reducing the concentration of disease-causing autoantibodies in autoimmune diseases. |
| ARGX-110 | A human monoclonal antibody that targets CD70, a protein involved in the activation of immune cells, to treat cancer and autoimmune diseases. |
argenx SE's Porter Forces
Threat Of Substitutes
The threat of substitutes for argenx SE is moderate due to the availability of alternative treatments for autoimmune diseases.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of argenx SE's products and the lack of alternative treatments.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the dependence on a few key suppliers for raw materials and manufacturing services.
Threat Of New Entrants
The threat of new entrants is high due to the growing interest in autoimmune disease treatments and the potential for new companies to enter the market.
Intensity Of Rivalry
The intensity of rivalry is high due to the competitive nature of the biotechnology industry and the presence of established companies in the market.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.52% |
| Debt Cost | 5.21% |
| Equity Weight | 99.48% |
| Equity Cost | 5.78% |
| WACC | 5.77% |
| Leverage | 0.53% |
argenx SE : Quality Control
argenx SE passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| UCB.BR | UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as … |
| NOVO-B.CO | Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. … |
| GLPG.AS | Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that … |
| STMN.SW | Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novo Nordisk
A-Score
1-Year Total Return ->
🥈
Genmab
A-Score
1-Year Total Return ->
🥉
UCB
A-Score
1-Year Total Return ->
4
Argenx
A-Score
1-Year Total Return ->
5
Straumann
A-Score
1-Year Total Return ->
6
